Enovis (NYSE:ENOV) Issues FY 2024 Earnings Guidance

Enovis (NYSE:ENOV) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 2.750-2.800 for the period, compared to the consensus estimate of 2.710. The company issued revenue guidance of $2.1 billion-$2.1 billion, compared to the consensus revenue estimate of $2.1 billion.

Wall Street Analysts Forecast Growth

ENOV has been the topic of a number of research reports. JMP Securities started coverage on shares of Enovis in a report on Thursday, October 3rd. They set an “outperform” rating and a $62.00 target price on the stock. JPMorgan Chase & Co. lowered their price objective on Enovis from $53.00 to $50.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th. Needham & Company LLC decreased their price target on Enovis from $82.00 to $65.00 and set a “buy” rating for the company in a report on Thursday, August 8th. Finally, Evercore ISI cut their target price on Enovis from $62.00 to $58.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 1st. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $67.00.

Enovis Stock Up 0.7 %

Enovis stock opened at $43.32 on Wednesday. The stock has a 50-day simple moving average of $42.16 and a 200-day simple moving average of $45.62. The company has a market capitalization of $2.42 billion, a P/E ratio of -26.10 and a beta of 1.91. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.08 and a current ratio of 2.26. Enovis has a fifty-two week low of $38.27 and a fifty-two week high of $65.03.

Enovis (NYSE:ENOV) last announced its earnings results on Wednesday, August 7th. The company reported $0.62 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.03. The business had revenue of $525.20 million for the quarter, compared to analysts’ expectations of $525.99 million. Enovis had a negative net margin of 4.73% and a positive return on equity of 4.06%. The company’s quarterly revenue was up 22.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.61 EPS. Equities research analysts expect that Enovis will post 2.7 earnings per share for the current year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.